Form 8-K Axsome Therapeutics, For: Aug 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cowen Maintains Positive View on Axsome Therapeutics (AXSM) Despite PDUFA Delay
August 23, 2021 12:58 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $125.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the FDA informed the company last Friday that the Agency would not complete the review of the NDA submission regarding AXS-05 in MDD by the target PDUFA... More
